Hemolung体外二氧化碳清除治疗急性呼吸衰竭患者:多中心回顾性队列研究
该多中心、跨国回顾性队列研究基于Hemolung登记库(2013年4月至2021年6月,57个ICU)纳入159例急性呼吸衰竭接受Hemolung治疗的患者,比较ICU存活与死亡患者的特征,并用多因素logistic回归识别与ICU存活相关的变量。65例(41%)存活至ICU出院;存活率以哮喘持续状态最高(86%),其次为ARDS(52%)和COVID-19 ARDS(31%)。所有患者PaCO2显著降低、pH改善且机械通气支持减少;死亡患者年龄更大、P/F更低、辅助治疗使用更多,存活与死亡患者并发症无差异。多因素回归显示非COVID-19 ARDS、年龄<65岁及启动ECCO2R时P/F与ICU存活独立相关(P/F 100-200 vs <100:OR 6.57,95%CI 2.03-21.33)。
要点
- 159例急性呼吸衰竭接受Hemolung ECCO2R的患者中65例(41%)存活至ICU出院。
- 存活率:哮喘持续状态86%,ARDS 52%,COVID-19 ARDS 31%。
- 所有患者启动ECCO2R后4小时内PaCO2显著降低、pH改善并减少机械通气支持。
- 多因素回归:非COVID-19 ARDS、年龄<65岁、启动时P/F 100-200(vs <100)与ICU存活独立相关(OR 6.57,95%CI 2.03-21.33)。
- 存活与死亡患者并发症无差异;死亡患者年龄更大、P/F更低、辅助治疗使用更多。
适用人群与场景
- 接受Hemolung治疗的急性呼吸衰竭患者,数据来自2013年4月至2021年6月Hemolung登记库中57个ICU贡献的去标识数据。
- 存活至ICU出院者与死亡者进行比较;多因素logistic回归分析用于识别与ICU存活相关的变量。
研究设计与关键结果
- 研究设计:多中心、跨国、回顾性审查;纳入159例接受Hemolung治疗的急性呼吸衰竭患者。
- 主要结果:65例(41%)存活至ICU出院。
- 存活率:哮喘持续状态86%,ARDS 52%,COVID-19 ARDS 31%。
- 所有患者PaCO2显著降低、pH改善且机械通气支持减少;启动ECCO2R后4小时内即观察到高碳酸血症酸中毒显著改善并减少通气支持。
- 死亡患者年龄更大、PaO2:FIO2(P/F)更低、辅助治疗使用更多;存活与死亡患者并发症无差异。
- 多因素回归分析:非COVID-19 ARDS、年龄小于65岁、启动ECCO2R时P/F与ICU存活独立相关(P/F 100-200 vs <100:OR 6.57,95%CI 2.03-21.33)。
证据类型、等级与局限
- 证据类型:多中心、跨国、回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,非COVID-19 ARDS、年龄及启动ECCO2R时P/F与存活独立相关,可能有助于临床实践中的病例选择及未来研究。
- 作者指出ECCO2R设备可有效降低高碳酸血症和机械通气支持,但尚未显示降低死亡率,原因可能在于病例选择、设备性能、熟悉程度或管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Extracorporeal carbon dioxide removal (ECCO 2 R) devices are effective in reducing hypercapnia and mechanical ventilation support but have not been shown to reduce mortality. This may be due to case selection, device performance, familiarity, or the management. The objective of this study is to investigate the effectiveness and safety of a single ECCO 2 R device (Hemolung) in patients with acute respiratory failure and identify variables associated with survival that could help case selection in clinical practice as well as future research.
DESIGN: Multicenter, multinational, retrospective review.
SETTING: Data from the Hemolung Registry between April 2013 and June 2021, where 57 ICUs contributed deidentified data.
PATIENTS: Patients with acute respiratory failure treated with the Hemolung. The characteristics of patients who survived to ICU discharge were compared with those who died. Multivariable logistical regression analysis was used to identify variables associated with ICU survival.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of the 159 patients included, 65 (41%) survived to ICU discharge. The survival was highest in status asthmaticus (86%), followed by acute respiratory distress syndrome (ARDS) (52%) and COVID-19 ARDS (31%). All patients had a significant reduction in Pa co2 and improvement in pH with reduction in mechanical ventilation support. Patients who died were older, had a lower Pa o2 :F io2 (P/F) and higher use of adjunctive therapies. There was no difference in the complications between patients who survived to those who died. Multivariable regression analysis showed non-COVID-19 ARDS, age less than 65 years, and P/F at initiation of ECCO 2 R to be independently associated with survival to ICU discharge (P/F 100-200 vs <100: odds ratio, 6.57; 95% CI, 2.03-21.33).
CONCLUSIONS: Significant improvement in hypercapnic acidosis along with reduction in ventilation supports was noted within 4 hours of initiating ECCO 2 R. Non-COVID-19 ARDS, age, and P/F at commencement of ECCO 2 R were independently associated with survival.
参考来源
- Tiruvoipati R, Akkanti B, Dinh K, et al. Extracorporeal Carbon Dioxide Removal With the Hemolung in Patients With Acute Respiratory Failure: A Multicenter Retrospective Cohort Study. Crit Care Med. 2023. PMID: 36942957. doi:10.1097/CCM.0000000000005845
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。